WOBURN, Mass. – Swiss biopharmaceutical firm SQ Innovation has expanded its U.S. presence with a new 2,300-square-foot lease at Tower Office Park in Woburn, marking another milestone in the company’s rapid growth.
The new satellite location will support light manufacturing and administrative operations, complementing SQ Innovation’s primary American site in Burlington, Massachusetts.
Founded in 2019, SQ Innovation specializes in developing novel subcutaneous drug delivery therapies that enable patients to receive treatments traditionally administered in hospitals from the comfort of their homes. The company recently achieved a major regulatory milestone with U.S. FDA approval of Lasix ONYU on October 7, a therapy designed to treat fluid overload caused by worsening heart failure.
In addition to its Massachusetts locations, SQ Innovation maintains operations in Switzerland and The Netherlands, reinforcing its international footprint in the life sciences sector.
The Woburn lease was brokered by Cummings Properties senior leasing director Mike Truesdale and Jason Rexinis of Colliers.
“We have a strong history with Jason and the Colliers team,” said Truesdale. “They understand the strength and flexibility of our portfolio, which allows us to deliver specialized, high-value spaces that align with each client’s unique operational needs.”
Truesdale added that Tower Office Park offered the “ideal combination of size, functionality, and convenience” for SQ Innovation’s expansion.
“This Tower Office Park location provides private loading, convenient highway access via I-93 and I-95, and close proximity to SQ Innovation’s Burlington facility—all key factors for a growing life sciences firm,” he said.
